Clinical Scorecard: CDC recommends 2026–2027 COVID vaccines for all adults
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: CDC recommends 2026–2027 COVID vaccines for all adults
Key Mechanisms
CDC says updated vaccines are intended to improve protection against currently circulating SARS-CoV-2 strains as vaccine-derived and infection-acquired immunity decline over time.
Target Population
Patients or participants described in the source article.
Care Setting
Care setting described in the source article.
Key Highlights
CDC recommends 2026–2027 COVID-19 vaccination for all adults aged 18 years and older, regardless of prior vaccination or SARS-CoV-2 infection.
Vaccination is emphasized for adults aged 65 years and older, people at increased risk of severe COVID-19, long-term care facility residents, people never vaccinated against COVID-19, and people with a history of long COVID.
Vaccination is recommended for moderately or severely immunocompromised children aged 6 months through 17 years; for other children in this age group, vaccination is recommended through shared clinical decision-making.
After COVID-19, vaccination may be delayed for 3 months after symptom onset or, if asymptomatic, after a positive test; earlier vaccination may be appropriate based on individual and local risk factors.
Four updated products are listed, with eligibility varying by age; no product is preferred when multiple products are recommended for a patient's age group.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Adults aged 18 years and older, including those previously vaccinated or infected; children aged 6 months through 17 years, with recommendations varying by immune status.
Product eligibility varies by age: Spikevax from 6 months, Comirnaty from 5 years, and mNexspike and Nuvaxovid from 12 years. No product is preferred when multiple products are recommended for the patient's age group.
Clinical Best Practices
Use shared clinical decision-making for vaccination of children aged 6 months through 17 years who are not moderately or severely immunocompromised.
When considering vaccination after recent infection, account for the 3-month delay option and the patient's risk of severe illness, risks to close contacts, and local COVID-19 activity.
Consult specialized CDC guidance for vaccination schedules in moderately or severely immunocompromised individuals.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.
